Moreover, Ganaxolone is a synthetic allopregnanolone analog [14], which was first authorized in March 2022 in the USA for treating seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients aged 2 years and older [15]. Here, CDKL5 is linked to craniodiaphyseal dysplasia.